Aethlon Medical (Aethlon Medical) Cash, Cash Equivalents, Marketable Securities : $7.97 Mil (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Aethlon Medical Cash, Cash Equivalents, Marketable Securities?

Aethlon Medical's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($12.90 Mil) to Sep. 2023 ($10.18 Mil) but then stayed the same from Sep. 2023 ($10.18 Mil) to Dec. 2023 ($7.97 Mil).

Aethlon Medical's annual cash, cash equivalents, marketable securities increased from Mar. 2021 ($9.86 Mil) to Mar. 2022 ($17.07 Mil) but then declined from Mar. 2022 ($17.07 Mil) to Mar. 2023 ($14.53 Mil).

Aethlon Medical Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Aethlon Medical's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aethlon Medical Cash, Cash Equivalents, Marketable Securities Chart

Aethlon Medical Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

3.83

9.61

9.86

17.07

14.53

Aethlon Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															17.50	14.53	12.90	10.18	7.97

Aethlon Medical Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Aethlon Medical (NAS:AEMD) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Aethlon Medical Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Aethlon Medical's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aethlon Medical (Aethlon Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aethlon Medical Inc (NAS:AEMD) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

EJU0:Germany

Address

11555 Sorrento Valley Road, Suite 203, San Diego, CA, USA, 92121

Website

https://www.aethlonmedical.com

Aethlon Medical Inc is a medical technology company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

Executives

Nicolas Gikakis	director	11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO CA 92121
Lee D Arnold	officer: Chief Scientific Officer	C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Angela Rossetti	director	PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Steven P Larosa	officer: Chief Medical Officer	9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA 92123
Chetan Shah	director	9 GRACE HILL COURT, TITUSVILLE NJ 08560
Fisher Charles J Jr	director	C/O AETHLON MEDICAL, INC., 9635 GRANITE RIDGE DR., SUITE 100, SAN DIEGO CA 92123
Guy F. Cipriani	director	1727 EAGLERIDGE DRIVE, BELLINGHAM WA 98226
Sabrina Martucci Johnson	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Rodell Timothy C Jr	officer: Interim CEO	201 MIDLAND AVE, ASPEN CO 81611
Weiner Family Revocable Trust Ellen R.	10 percent owner	10645 N. TATUM BOULEVARD, SUITE 200-166, PHOENIX AZ 85028
Phillip A Ward	director	8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Thomas V Wornham	director	8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Rodney S Kenley	director, officer: President	9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
James B Frakes	officer: Chief Financial Officer	9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
Barry Franklyn S Jr	director	1141 DELAWARE AVENUE #3N, BUFFALO NY 14209